WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 285-292

  Zhao, Yan ^a   Liu, Yan ^a   Zhang, Weiping ^a   Xue, Jiahong ^a   Wu, Yue Z ^a   Xu, Wei ^a   Liang, Xiao ^a   Chen, Tao ^a   Kishimoto, Chiharu ^c   Yuan, Zuyi ^a,b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Inflammation; Macrophage; WIN55212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; APOLIPOPROTEIN E; CANNABINOID 2 RECEPTOR; CHOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOGLYCOLIC ACID; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATTENUATION; CELL AGGREGATION; CELL ISOLATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIPID DIET; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZOXAZINES; CYTOKINES; DIET, ATHEROGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MORPHOLINES; NAPHTHALENES; NF-KAPPA B; PLAQUE, ATHEROSCLEROTIC; RANDOM ALLOCATION; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER;

EID: 78049273704     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.027     Document Type: Article

References (44)

1. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. 2006, 396:113-116.
2. Boyle J.J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr. Vasc. Pharmacol. 2005, 3:63-68.
3. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 396:141-149.
4. Dansky H.M., Charlton S.A., Harper M.M., Smith J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 1997, 94:4642-4646.
5. De Filippis D., Russo A., De Stefano D., Maiuri M.C., Esposito G., Cinelli M.P., Pietropaolo C., Carnuccio R., Russo G., Iuvone T. Local administration of WIN 55, 212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J. Mol. Med. 2007, 85:635-645.
6. Dol-Gleizes F., Paumelle R., Visentin V., Mares A.M., Desitter P., Hennuyer N., Gilde A., Staels B., Schaeffer P., Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:12-18.
7. Dubinski A., Zdrojewicz Z. The role of interleukin-6 in development and progression of atherosclerosis. Pol. Merkuriusz Lek. 2007, 22:291-294.
8. Ghosh S., Azhahianambi P., de la Fuente J. Control of ticks of ruminants, with special emphasis on livestock farming systems in India: present and future possibilities for integrated control - a review. Exp. Appl. Acarol. 2006, 40:49-66.
9. Ghosh S., Preet A., Groopman J.E., Ganju R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol. 2006, 43:2169-2179.
10. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., Shohami E., Spatz M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 2004, 132:87-92.
11. Gotsman I., Grabie N., Gupta R., Dacosta R., MacConmara M., Lederer J., Sukhova G., Witztum J.L., Sharpe A.H., Lichtman A.H. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
12. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 1998, 2:275-281.
13. Hajrasouliha A.R., Tavakoli S., Ghasemi M., Jabehdar-Maralani P., Sadeghipour H., Ebrahimi F., Dehpour A.R. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur. J. Pharmacol. 2008, 579:246-252.
14. Ihenetu K., Molleman A., Parsons M.E., Whelan C.J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur. J. Pharmacol. 2003, 458:207-215.
15. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 2002, 55:619-625.
16. Kenneth J. Severe acute respiratory syndrome (SARS): the new epidemic. Natl Med. J. India 2003, 16:115-116.
17. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008, 79:360-376.
18. Krylatov A.V., Bernatskaia N.A., Maslov L.N., Pertwee R.G., Mechoulam R., Stefano G.B., Sharaevskii M.A., Sal'nikova O.M. Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors. Ross. Fiziol. Z. Im. I.M. Sechenova 2002, 88:560-567.
19. Lagneux C., Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol. 2001, 132:793-796.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
21. Maccarrone M., Fiori A., Bari M., Granata F., Gasperi V., De Stefano M.E., Finazzi-Agro A., Strom R. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb. Haemost. 2006, 95:117-127.
22. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 2006, 46:101-122.
23. Marchalant Y., Rosi S., Wenk G.L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 2007, 144:1516-1522.
24. McKellar G.E., McCarey D.W., Sattar N., McInnes I.B. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 2009, 6:410-417.
25. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., Di Marzo V., Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92:1327-1339.
26. Montecucco F., Burger F., Mach F., Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:1145-1155.
27. Mormina M.E., Thakur S., Molleman A., Whelan C.J., Baydoun A.R. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur. J. Pharmacol. 2006, 540:183-190.
28. Mukhopadhyay P., Batkai S., Rajesh M., Czifra N., Harvey-White J., Hasko G., Zsengeller Z., Gerard N.P., Liaudet L., Kunos G., Pacher P. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 2007, 50:528-536.
29. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler. 2004, 10:158-164.
30. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?. Arterioscler. Thromb. Vasc. Biol. 2009, 29:7-9.
31. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
32. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Huffman J.W., Csiszar A., Ungvari Z., Mackie K., Chatterjee S., Pacher P. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:2210-2218.
33. Rajesh M., Mukhopadhyay P., Hasko G., Huffman J.W., Mackie K., Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 2008, 153:347-357.
34. Sacerdote P., Martucci C., Vaccani A., Bariselli F., Panerai A.E., Colombo A., Parolaro D., Massi P. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 2005, 159:97-105.
35. Shmist Y.A., Goncharov I., Eichler M., Shneyvays V., Isaac A., Vogel Z., Shainberg A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol. Cell. Biochem. 2006, 283:75-83.
36. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996, 278:989-999.
37. Song L., Leung C., Schindler C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 2001, 108:251-259.
38. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., Karsak M., Zimmer A., Frossard J.L., Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434:782-786.
39. Sugamura K., Sugiyama S., Nozaki T., Matsuzawa Y., Izumiya Y., Miyata K., Nakayama M., Kaikita K., Obata T., Takeya M., Ogawa H. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009, 119:28-36.
40. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
41. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., Roth M.D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 2002, 133:124-131.
42. Yuan Z., Kishimoto C., Sano H., Shioji K., Xu Y., Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:899-906.
43. Zhao Y., Yuan Z., Liu Y., Xue J., Tian Y., Liu W., Zhang W., Shen Y., Xu W., Liang X., Chen T. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J. Cardiovasc. Pharmacol. 2010, 55:292-298.
44. Zhou X., Nicoletti A., Elhage R., Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919-2922.